Pubertal Growth (TPG) in Adolescents with Idiopathic Growth Hormone Deficiency (GHD), Turner Syndrome (TS), Short Stature Born Small for Gestational Age (SGA) and Idiopathic Short Stature (ISS) Documents a Minor Role for GH Doses in Puberty.

2010 ◽  
pp. P1-680-P1-680
Author(s):  
MB Ranke ◽  
A Lindberg
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Short Stature ◽  
Turner Syndrome ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Hormone Deficiency ◽  
Minor Role ◽  
Pubertal Growth ◽  
A Minor

scholarly journals Adherence to treatment in children with growth hormone deficiency, small for gestational age and Turner syndrome in Mexico: results of the Easypod™ connect observational study (ECOS)

2020 ◽  
Vol 43 (10) ◽  
pp. 1447-1452
Author(s):  
A. Blanco-López ◽  
C. Antillón-Ferreira ◽  
E. Saavedra-Castillo ◽  
M. Barrientos-Pérez ◽  
H. Rivero-Escalante ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Observational Study ◽  
Growth Hormone Deficiency ◽  
Turner Syndrome ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Hormone Deficiency ◽  
Height Velocity ◽  
Electronic Injection

Abstract Background Assessing adherence to growth hormone (GH) is challenging. The Easypod™ connect device delivers pre-set doses of recombinant human GH (r-hGH) and stores a digital record of adherence that can be shared with healthcare provider. We assessed adherence to r-hGH delivered with Easypod™ according to the approved pediatric indications for r-hGH: growth hormone deficiency (GHD), born small for gestational age (SGA) who failed to show catch-up growth and Turner syndrome (TS). Methods ECOS (NCT01555528) was a multicenter (24 countries), 5-year, longitudinal, observational study, which aimed to evaluate country-specific adherence to r-hGH therapy prescribed via the Easypod™ electronic injection device. The primary endpoint was yearly adherence. Secondary endpoints were height velocity, height velocity standard deviation scores (SDS), height, height SDS and IGF-1 concentrations. Clinical and auxological data were obtained from medical records and adherence from Easypod™ logs. Results This study included 147 Easypod™-naïve Mexican children assessed during 3 years (mean age: 9.96 ± 3.41 years, 56.8% boys, mean height SDS at baseline: − 2.17 ± 0.97): 118 with GHD, 24 SGA and 5 with TS. A total of 105 (71.4%) patients were GH naïve. Overall median adherence was > 90% over the first year of treatment and > 80% at 3 years. Adherence was not different by r-hGH indication or between GH-naïve or experienced patients. At 1-year follow-up, mean change in height SDS was 0.57 ± 0.34, whereas mean height velocity SDS was 2.85 ± 2.51. In all, 84.7% patients had normal IGF-1 concentrations at 1-year follow-up. Adherence was associated with change in height SDS (r = 0.239, p = 0.005) and height velocity SDS (r = 0.194, p = 0.027). Conclusion Adherence rates with the Easypod™ device are high and maintained over time in GHD, SGA and TS Easypod™-naïve Mexican patients. High adherence is associated with better outcomes. Easypod™ assists physicians in monitoring adherence to r-hGH.

Decrease of small dense LDL and lipoprotein-associated phospholipase A2 due to human growth hormone treatment in short children with growth hormone deficiency and small for gestational age status

2016 ◽  
Vol 29 (2) ◽  
Author(s):  
Andreas Krebs ◽  
Thomas Kratzin ◽  
Jürgen Doerfer ◽  
Karl Winkler ◽  
Michael Wurm ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Human Growth ◽  
Hormone Deficiency ◽  
Cardiovascular Risks ◽  
Small Dense Ldl

AbstractGrowth hormone deficiency (GHD) and small for gestational age (SGA) status are associated with cardiovascular risks. We therefore, investigated antiatherogenic effects of growth hormone (GH).Subfractions of low-density lipoprotein (LDL) and high-density lipoprotein (HDL), lipoprotein-associated phospholipase AThe overall group showed post-treatment reductions of LDL cholesterol (LDL-C) (p=0.016), small-dense LDL cholesterol (sdLDL-C, p<0.001), Lp-PLA2 (p<0.001), and hsCRP (p=0.005), but increase of HDL2a cholesterol (HDL2a-C, p=0.025). SGA children revealed significant correlations between Lp-PLA2 and LDL-C and sdLDL-C both before and after GH, significant reductions of sdLDL-C, Lp-PLA2, hsCRP, and an increase of HDL2a-C. GHD children showed the same lipid responses, though not significantly.Children with GHD or born SGA may benefit from GH by growth acceleration and reduction of cardiovascular long-term risks.

scholarly journals Three years of growth hormone therapy in children born small for gestational age: results from the ANSWER Program

2018 ◽  
Vol 7 (10) ◽  
pp. 1096-1104 ◽  
Author(s):  
Robert Rapaport ◽  
Peter A Lee ◽  
Judith L Ross ◽  
Paul Saenger ◽  
Vlady Ostrow ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Short Stature ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Growth Failure ◽  
Hormone Deficiency ◽  
Birth Size ◽  
Growth Disorders ◽  
Gh Therapy ◽  
The Impact

Growth hormone (GH) is used to treat short stature and growth failure associated with growth disorders. Birth size and GH status variably modulate response to GH therapy. The aim of this study was to determine the effect of birth size on response to GH therapy, and to determine the impact of GH status in patients born small for gestational age (SGA) on response to GH therapy. Data from the prospective, non-interventional American Norditropin Studies: Web-Enabled Research (ANSWER) Program was analyzed for several growth outcomes in response to GH therapy over 3 years. GH-naïve children from the ANSWER Program were included in this analysis: SGA with peak GH ≥10 ng/mL (20 mIU/L), SGA with peak GH <10 ng/mL (20 mIU/L), isolated growth hormone deficiency (IGHD) born SGA, IGHD not born SGA and idiopathic short stature. For patients with IGHD, those who did not meet criteria for SGA at birth showed greater improvements in height SDS and BMI SDS than patients with IGHD who met criteria for SGA at birth. For patients born SGA, response to GH therapy varied with GH status. Therefore, unlike previous guidelines, we recommend that GH status be established in patients born SGA to optimize GH therapy.

scholarly journals Evaluation of Clinical Features and Growth Hormone Deficiency in Short Children Born Small For Gestational Age

2018 ◽  
Vol 40 (3) ◽  
pp. 253-257
Author(s):  
Tomomi IKEGAMI ◽  
Shunsuke ARAKI ◽  
Mami KUWAMURA ◽  
Aoi TAKU ◽  
Reiko SAITO ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Clinical Features ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Hormone Deficiency ◽  
Short Children
Sign in / Sign up

Export Citation Format

Share Document